DE69327542T2 - Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung - Google Patents

Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung

Info

Publication number
DE69327542T2
DE69327542T2 DE69327542T DE69327542T DE69327542T2 DE 69327542 T2 DE69327542 T2 DE 69327542T2 DE 69327542 T DE69327542 T DE 69327542T DE 69327542 T DE69327542 T DE 69327542T DE 69327542 T2 DE69327542 T2 DE 69327542T2
Authority
DE
Germany
Prior art keywords
microsphere
antipsychotic
biocompatible polymer
dispense
microball
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69327542T
Other languages
English (en)
Other versions
DE69327542D1 (de
Inventor
Shigemi Kino
Tomonori Osajima
Hiroaki Mizuta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18255017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69327542(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Welfide Corp filed Critical Welfide Corp
Application granted granted Critical
Publication of DE69327542D1 publication Critical patent/DE69327542D1/de
Publication of DE69327542T2 publication Critical patent/DE69327542T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
DE69327542T 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung Revoked DE69327542T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33244192 1992-11-17
PCT/JP1993/001673 WO1994010982A1 (en) 1992-11-17 1993-11-15 Sustained-release microsphere containing antipsychotic and process for producing the same

Publications (2)

Publication Number Publication Date
DE69327542D1 DE69327542D1 (de) 2000-02-10
DE69327542T2 true DE69327542T2 (de) 2000-07-06

Family

ID=18255017

Family Applications (2)

Application Number Title Priority Date Filing Date
DE0669128T Pending DE669128T1 (de) 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung.
DE69327542T Revoked DE69327542T2 (de) 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE0669128T Pending DE669128T1 (de) 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung.

Country Status (11)

Country Link
US (2) US5656299A (de)
EP (1) EP0669128B1 (de)
KR (1) KR100333115B1 (de)
AT (1) ATE188375T1 (de)
CA (1) CA2148823C (de)
DE (2) DE669128T1 (de)
DK (1) DK0669128T3 (de)
ES (1) ES2077547T3 (de)
GR (2) GR960300020T1 (de)
PT (1) PT669128E (de)
WO (1) WO1994010982A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
CZ293764B6 (cs) * 1993-11-19 2004-07-14 Janssen Pharmaceutica N. V. Farmaceutický prostředek s dostatečným a dlouhodobým uvolňováním léčiva, biodegradovatelné a biokompatibilní mikročástice, způsob jejich výroby a použití
WO1995013799A1 (en) * 1993-11-19 1995-05-26 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
EP1210942B1 (de) * 1996-05-07 2007-03-21 Alkermes, Inc. Micropartikel
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
CN1219872A (zh) * 1996-05-24 1999-06-16 血管技术药物公司 治疗或预防身体通道疾病的组合物和方法
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US6854841B1 (en) * 1998-04-17 2005-02-15 Elesys, Inc. Point-of-incidence ink-curing mechanisms for radial printing
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
GB9817078D0 (en) * 1998-08-05 1998-10-07 Habib Nagy A Device for liver surgery
GEP20094818B (en) * 1998-09-30 2009-11-10 Lilly Co Eli 2-methyl-thieno-benzodiaze-pine formulation
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
EP2266542A3 (de) * 1998-10-01 2013-07-31 Elan Pharma International Limited Nanopartikelformulierungen mit kontrollierter Wirkstofffreisetzung
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
NZ513895A (en) * 1999-02-23 2001-09-28 Univ British Columbia Compositions and methods for improving integrity of compromised body passageways and cavities
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
JP2004515527A (ja) * 2000-12-13 2004-05-27 メルクル・ゲーエムベーハー 放出特性改良微粒子およびその製造方法
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
JP2004535431A (ja) 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
IL159624A0 (en) 2001-06-29 2004-06-01 Medgraft Microtech Inc Biodegradable injectable implants and related methods of manufacture and use
US7615233B2 (en) 2001-07-10 2009-11-10 Canon Kabushiki Kaisha Particulate construct comprising polyhydroxyalkanoate and method for producing it
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
US6699963B2 (en) * 2002-03-18 2004-03-02 The Procter & Gamble Company Grinding process for plastic material and compositions therefrom
DK1487416T3 (da) * 2002-03-26 2010-03-29 Teva Pharma Lægemiddelmikropartikler
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR20050056222A (ko) * 2002-09-30 2005-06-14 아쿠스피어 인코포레이티드 흡입용 지속 방출형 다공성 미세입자
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
WO2004073749A1 (ja) * 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited 徐放性製剤用の分散剤
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
EP2633853A1 (de) * 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Langzeitabgabe von Lieferungsformulierungen und Verwendungsverfahren dafür
JP5030292B2 (ja) 2004-04-15 2012-09-19 アミリン・ファーマシューティカルズ，インコーポレイテッド ポリマーを基にした持続放出性装置
ES2527286T3 (es) * 2004-04-30 2015-01-22 Abraxis Bioscience, Llc Microesferas de liberación sostenida y métodos de fabricación y uso de las mismas
ITMI20042232A1 (it) * 2004-11-19 2005-02-19 Unihart Corp Composizione farmaceutica contenente clozapina
PL1838716T3 (pl) 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
MX2008000573A (es) * 2005-07-18 2008-03-14 Univ Pennsylvania Implantes que contienen farmacos y metodos de uso de los mismos.
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7669732B2 (en) * 2005-10-25 2010-03-02 Imi Cornelius Inc. Cup lid dispenser
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US7811604B1 (en) * 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US7538652B2 (en) * 2006-08-29 2009-05-26 International Business Machines Corporation Electrical component tuned by conductive layer deletion
KR20090094811A (ko) * 2006-10-05 2009-09-08 파나세아 바이오테크 리미티드 새로운 형태의 주입형 데포조성물 및 이를 조제하기 위한 방법
US20080233199A1 (en) * 2007-03-22 2008-09-25 Alkermes, Inc. Coacervation Process
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
WO2008157540A1 (en) * 2007-06-20 2008-12-24 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
US10632079B2 (en) 2007-06-25 2020-04-28 Otsuka Pharmaceuticals Co., Ltd. Microspheres having core/shell structure
US9161943B2 (en) * 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
JP5850501B2 (ja) 2009-06-09 2016-02-03 ニューロナノ アーベー 微小電極
KR20150006083A (ko) 2009-09-28 2015-01-15 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US8641900B2 (en) * 2009-11-05 2014-02-04 Taiwan Biotech Co., Ltd Method and device for continuously preparing microspheres, and collection unit thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN104127385B (zh) 2011-04-25 2017-08-04 山东绿叶制药有限公司 利培酮缓释微球组合物
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
WO2014164754A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
KR101738127B1 (ko) * 2014-08-08 2017-05-22 (주)비씨월드제약 약물 함유 서방성 미립자의 제조 방법
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3733694A1 (de) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN114126592A (zh) * 2019-07-12 2022-03-01 G2G生物公司 含有利凡斯的明的长效制剂及其制备方法
CN111991397B (zh) * 2020-10-13 2021-09-10 深圳善康医疗健康产业有限公司 一种氟哌噻吨美利曲辛微球及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS568318A (en) * 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
FR2534139B1 (fr) * 1982-10-07 1986-08-29 Laruelle Claude Nouvelle forme galenique du sulpiride, son procede de preparation et medicament comprenant cette nouvelle forme
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.

Also Published As

Publication number Publication date
ATE188375T1 (de) 2000-01-15
US5871778A (en) 1999-02-16
EP0669128B1 (de) 2000-01-05
EP0669128A1 (de) 1995-08-30
KR950703936A (ko) 1995-11-17
GR960300020T1 (en) 1996-03-31
US5656299A (en) 1997-08-12
ES2077547T1 (es) 1995-12-01
KR100333115B1 (ko) 2002-12-02
EP0669128A4 (de) 1996-09-25
CA2148823A1 (en) 1994-05-26
DE669128T1 (de) 1996-03-14
DE69327542D1 (de) 2000-02-10
CA2148823C (en) 1999-03-09
GR3033016T3 (en) 2000-08-31
ES2077547T3 (es) 2000-06-16
WO1994010982A1 (en) 1994-05-26
PT669128E (pt) 2000-06-30
DK0669128T3 (da) 2000-06-19

Similar Documents

Publication Publication Date Title
DE69327542T2 (de) Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
Devlin et al. Healing of tooth extraction sockets in experimental diabetes mellitus
DE69819694T2 (de) Subkutan oder intradermal injizierbares implantat in der plastischen oder wiederherstellenden chirurgie
DE3778244D1 (de) Oestradiol-implantat und verfahren zu seiner herstellung.
IL78826A0 (en) Sustained release pharmaceutical compositions incorporating degradable delivery system of drugs
EP0301856A3 (en) Delivery system
ITPD910229A1 (it) Tessuto non tessuto essenzialmente costituito da derivati dell'acido ialuronico
ATE261278T1 (de) Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen
ATE125158T1 (de) Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven.
IE882727L (en) Sustained release pharmaceutical compositions
ATA154590A (de) Verfahren zur herstellung einer pharmazeutischen zubereitung in form von mikropartikeln zur herstellung von injizierbaren suspensionen zur verzoegerten und kontrollierten abgabe eines peptids
DE69121561D1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
US20110244006A1 (en) Microsphere skin treatment
FR2686250B1 (de)
DE69703430T2 (de) Polymere mit kontrolliertem physikalischen zustand und bioerodierbarkeit
DE3889933D1 (de) Perorale Arzneimittelzubereitung mit verzögerter Wirkstofffreigabe.
DO et al. Optimizing Injections of Poly–L–Lactic Acid: The 6-Step Technique
ATA223591A (de) Verfahren zur herstellung einer zur kontinuierlichen und kontrollierten abgabe eines natürlichen oder synthetischen peptids bestimmten pharmazeutischen zusammensetzung, insbesondere in form von mikrokapseln bzw. implantaten
JPS6450824A (en) Improved immunity for mammals

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: WELFIDE CORP., OSAKA, JP

8327 Change in the person/name/address of the patent owner

Owner name: MITSUBISHI PHARMA CORP., OSAKA, JP

8331 Complete revocation